Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | RAD51D S257_R259delinsK RAD51D G258Sfs*50 |
| Therapy | Rucaparib |
| Indication/Tumor Type | ovarian carcinoma |
| Response Type | predicted - resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RAD51D S257_R259delinsK RAD51D G258Sfs*50 | ovarian carcinoma | predicted - resistant | Rucaparib | Case Reports/Case Series | Actionable | In a clinical case study, an ovarian carcinoma patient harboring a RAD51D G258Sfs*50 germline mutation developed resistance to Rubraca (rucaparib) after acquisition of RAD51D S257_R259delinsK (PMID: 28588062). | 28588062 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (28588062) | Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. | Full reference... |